Evidence map›Paper›PMID 41133681›Full record

ArticleAntibodies (Basel, Switzerland)2025

A Robust, High-Titer, Semi-Automated, and In-Culture Antibody-Capturing Transient CHO Platform Technology.

Lauren Gebhardt, Molica Abel, Jing Zhou, Audrey M Vogt, Bo Hee Shin, Sarah L Herrick Wagman, Ana Santos, Jerome Puginier, Florian M Wurm, Maria J Wurm and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibodies (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Unique DNA impacts on transient Expi293Frontiers in bioengineering and biotechnology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lauren GebhardtBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.
Molica AbelBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.
Jing ZhouBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.
Audrey M VogtBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.
Bo Hee ShinBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.
Sarah L Herrick WagmanBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.
Ana SantosMagellanBiologics, Parque Tecnológico de Cantanhede Edificio III Laboratório 5, 3060-197 Cantanhede, Portugal.
Jerome PuginierMagellanBiologics, Parque Tecnológico de Cantanhede Edificio III Laboratório 5, 3060-197 Cantanhede, Portugal.
Florian M WurmMagellanBiologics, Parque Tecnológico de Cantanhede Edificio III Laboratório 5, 3060-197 Cantanhede, Portugal.ORCID 0000-0003-1114-4520
Maria J WurmMagellanBiologics, Parque Tecnológico de Cantanhede Edificio III Laboratório 5, 3060-197 Cantanhede, Portugal.
Guoying Grace YanBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.
Adedolapo AdeniyiBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.
Sean K H LimBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.
Will SomersBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.
Laura LinBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.ORCID 0000-0003-1619-7437
Aaron M D'AntonaBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.ORCID 0000-0003-0063-5594
Xiaotian ZhongBioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, 610 MainStreet, Cambridge, MA 02139, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent advances in antibody discovery technologies, especially progress in de novo synthesis through machine learning, have imposed a significant production challenge for the generation of a large diversity of antibodies against nearly any target of interest. There is a demand for the rapid production of dozens of purified antibodies in 10-milligram quantities sufficient for functional screening and molecular assessment studies.

objectivesTo meet this requirement, a semi-automated production methodology and workflow was developed to bridge the miniaturized high-throughput screenings (HTSs) and the conventional custom-scale workflow by taking advantage of four new technology applications.

methodsFirst, it exploited a novel, simple, high-titer transient expression system, "CHO4Tx RESULTS AND

conclusionsThis new production platform was proven to be robust and could be applied for the routine production of antibodies of sufficient quality and quantity in support of cell-based assays and biophysical characterization.

Indexed as

AKTA PureTMCHO4Tx®GenScript AmMag™ SA-Plusin-culture antibody capturingmagnetic ProA beadssemi-automationtransient gene expression

Identifiers

PMID41133681
PMCPMC12551003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.